Trajectories following Impella 5.5 support are associated with initial presentation acuity

Area of Science:

• Cardiology
• Mechanical Circulatory Support
• Heart Failure Management

Background:

• The Impella 5.5 is a temporary left ventricular assist device used for cardiogenic shock and high-risk cardiac interventions.
• Effective temporary mechanical circulatory support is crucial for managing complex cardiac conditions.

Purpose of the Study:

• To evaluate the outcomes of Impella 5.5 support in patients stratified by Society for Cardiovascular Angiography and Interventions (SCAI) shock stages.
• To determine the impact of presentation acuity on patient trajectories following Impella 5.5 implantation.

Main Methods:

• A retrospective analysis of 226 patients receiving Impella 5.5 support from October 2019 to January 2023.
• Patients were categorized based on SCAI shock stages (A-E).
• Immediate post-Impella 5.5 outcomes were assessed, including mortality, transition to advanced therapies, and survival to device removal.

Main Results:

• Mortality on Impella 5.5 was highest in SCAI stage E (35%) and lowest in stage A (3.2%).
• Transition to advanced therapies (durable LVAD/transplant) was most frequent in SCAI stages C-D (45% and 36%, respectively).
• Survival to Impella 5.5 removal without advanced therapies was highest in SCAI stages A-B (95% and 90%, respectively).

Conclusions:

• Patient stratification by presentation acuity is essential for optimizing Impella 5.5 utilization.
• Tailored temporary mechanical circulatory support based on SCAI stage can improve patient outcomes.
• Identifying appropriate candidates for Impella 5.5 can enhance its therapeutic benefit.